Harrow announces PharmaPack Direct-to-Prescriber cash-pay offering

Harrow (HROW) announced the launch of a new Direct-to-Prescriber cash-pay offering called PharmaPack, which expands the Company’s commitment to offering affordable FDA-approved branded products as alternatives to off-label compounded formulations. PharmaPack kits expand access to FDA-approved ophthalmic products for the millions of Americans each year who require infection control and treatment of pain and inflammation associated with cataract surgery. PharmaPack kits also remove insurance-related administrative complexity and reduce regulatory and medical-legal risk associated with off-label compounded products.